Compare CLRO & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLRO | PMCB |
|---|---|---|
| Founded | 1983 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 8.4M |
| IPO Year | N/A | N/A |
| Metric | CLRO | PMCB |
|---|---|---|
| Price | $6.47 | $0.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.6K | ★ 356.7K |
| Earning Date | 11-14-2025 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,386,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 174.10 | N/A |
| 52 Week Low | $3.83 | $0.63 |
| 52 Week High | $15.42 | $1.90 |
| Indicator | CLRO | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 54.88 | 43.10 |
| Support Level | $6.45 | $0.84 |
| Resistance Level | $7.16 | $1.05 |
| Average True Range (ATR) | 0.52 | 0.09 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 63.30 | 14.91 |
ClearOne Inc is a communications solutions company, which is engaged in designing, developing, and selling conferencing, collaboration, streaming, and digital signage solutions for audio, video, and visual communication. It sells its commercial products to end-users predominantly through a network of independent distributors, who in turn sell its products to dealers, systems integrators, and other resellers. Its products include DSP mixers, amplifiers, Video walls, professional cameras, and professional microphones among others. Geographically the firm has its business presence across the United States and international markets.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.